A panel of expert advisors for the Centers for Disease Control and Prevention on Friday voted 10 to four (with one abstention) in favor of lifting the pause on the Johnson & Johnson COVID-19 vaccine. The panel reaffirmed its recommendation for use of the one-shot vaccine in adults of all ages and sexes.

The reaffirmation will come with a new warning in the Food and Drug Administration’s emergency use authorization, which will note that the vaccine appears linked to an extremely rare—but life-threatening—condition that involves serious blood clots and low blood platelets, mainly in women younger than age 50. Experts have dubbed the condition “thrombosis with thrombocytopenia syndrome,” or TTS.